Demodicosis among immunocompromised patients:
a review

Marquardt-Feszler, Adriana; Cekała, Karolina; Dębska‐Ślizień, Alicja; Imko-Walczuk, Beata

doi:10.5114/ada.2022.120879

Cited by 3 publications

(2 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The precise etiology of demodicosis is unclear, but local and systemic immune status likely plays a role. Demodex ‐associated dermatoses have been reported in settings that include human immunodeficiency virus infection, solid organ transplantation, hematological malignancy, chemotherapy such as 6‐mercaptopurine and vincristine, and use of topical steroids 3,5,6 . In addition, studies have demonstrated that the density of Demodex mites on the skin is greater in patients undergoing treatment with immunosuppressive medications 7 .…”

Section: Discussionmentioning

confidence: 99%

“…Demodex-associated dermatoses have been reported in settings that include human immunodeficiency virus infection, solid organ transplantation, hematological malignancy, chemotherapy such as 6-mercaptopurine and vincristine, and use of topical steroids. 3,5,6 In addition, studies have demonstrated that the density of Demodex mites on the skin is greater in patients undergoing treatment with immunosuppressive medications. 7 The clinical morphology of demodicosis may include erythema, rosacea-like lesions and folliculitis, 8 and may mimic cutaneous lupus erythematosus or dermatomyositis, leading to further immunosuppressive treatment and in turn worsening of the eruption, as in our patient.…”

Section: F I G U R E 2 Demodex Mites In a Follicular Orifice (Hematox...mentioning

confidence: 99%

See 1 more Smart Citation

Iatrogenic Demodex folliculitis: A case report

et al. 2023

View full text Add to dashboard Cite

Demodex folliculorum is a commensal mite that inhabits the orifices of cutaneous pilosebaceous follicles. Overgrowth of these organisms can lead to Demodex folliculitis, which typically presents as papules and pustules predominantly involving the temples, cheeks, and occasionally the chest. We present a 51‐year‐old woman with iatrogenic Demodex folliculitis secondary to immunosuppressive treatment for an autoimmune connective tissue disease. Histopathological exam of a skin biopsy, which revealed follicular Demodex mites, confirmed the diagnosis. The eruption was treated with oral ivermectin and topical metronidazole gel, and the patient's immunosuppressive regimen was decreased, resulting in marked improvement in the eruption within 6 weeks and no worsening of her underlying autoimmune disorder. This case emphasizes the importance of considering Demodex folliculitis in the differential diagnosis of a new onset rash in the context of immunosuppressive treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: F I G U R E 2 Demodex Mites In a Follicular Orifice (Hematox...mentioning

confidence: 99%

Iatrogenic Demodex folliculitis: A case report

et al. 2023

View full text Add to dashboard Cite

show abstract

Demodicosis in an Immunocompetent Child

Izri,

Brun,

Bohelay

et al. 2025

The Journal of Pediatrics

View full text Add to dashboard Cite

Biologic therapy increases Demodex density in psoriasis patients

Aksoy,

Altıntaş Kakşi,

Gönüllü

et al. 2024

Int J Dermatology

View full text Add to dashboard Cite

BackgroundDemodex density is known to increase in various immunosuppressive conditions. The relationship between biologic therapy and Demodex density remains unknown. We aimed to investigate whether the density of Demodex mites is higher in psoriasis patients treated with biologic agents compared to treatment‐naive or topically treated patients.MethodsA cross‐sectional study was conducted, comparing psoriasis patients receiving biologic therapy (n = 34) with controls (n = 33). Demodex density was assessed using the standardized skin surface biopsy technique (SSSB). Statistical analysis was performed to compare the densities and prevalence of demodicosis between the two groups.ResultsDemodex density was significantly higher in the biologic therapy group compared to the control group on the right cheek (7.29 vs. 0.12/cm2; P = 0.001), left cheek (8.15 vs. 0.24/cm2; P = 0.002), and whole face (average of all four regions: 5.50 vs. 0.80/cm2; P = 0.001). The prevalence of demodicosis was significantly higher in the biologic therapy group on the forehead (35.3% vs. 12.1%; P = 0.043), right cheek (41.2% vs. 0%; P < 0.001), and left cheek (44.1% vs. 0%; P < 0.001). The frequency of cases with demodicosis in at least one localization was higher in the biological therapy group compared to the control group (61.8% vs. 15.2%; P < 0.001).ConclusionsPsoriasis patients receiving biologic therapy had a higher Demodex density and prevalence of demodicosis compared to controls. Biologics may lead to an increase in Demodex density by blocking specific cytokines, such as interleukin‐17 and tumor necrosis factor‐α, which play a role in immunity against Demodex. Further research is needed to explore the impact of different biological agents on Demodex density.

show abstract

Demodicosis among immunocompromised patients: a review

Cited by 3 publications

References 44 publications

Iatrogenic Demodex folliculitis: A case report

Iatrogenic Demodex folliculitis: A case report

Demodicosis in an Immunocompetent Child

Biologic therapy increases Demodex density in psoriasis patients

Contact Info

Product

Resources

About